Literature DB >> 31254048

Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome.

Jeffrey S Schachar1, Robert J Evans1, Graham E Parks2, Joao Zambon1, Gopal Badlani1, Stephen J Walker3,4.   

Abstract

INTRODUCTION AND HYPOTHESIS: Low anesthetic bladder capacity has been shown to be a biomarker for bladder-centric interstitial cystitis/bladder pain syndrome (IC/BPS). The goal of this study was to determine if histopathological evidence from bladder biopsies supports anesthetic bladder capacity (BC) as a marker to distinguish a bladder-centric IC/BPS subtype.
METHODS: From a review of our large IC/BPS cohort of patients undergoing hydrodistention, we identified a total of 41 patients with low BC (≤ 400 ml); an additional 41 consecutive patients with BC > 400 ml were selected as the comparator group. The original bladder mucosal biopsy pathology slides were re-reviewed by a single pathologist (blinded to patient information) using a standardized grading scale developed for this study.
RESULTS: Histologically, the low BC subjects exhibited higher levels of acute inflammation (p = 0.0299), chronic inflammation (p = 0.0139), and erosion on microscopy (p = 0.0155); however, there was no significant difference in mast cell count between groups (p = 0.4431). There was no significant gender difference between the groups; female patients were the majority in both groups (low BC: 94.12%, non-low BC: 100%; p = 0.1246). Individuals in the low BC group were older (p < 0.0001), had a higher incidence of Hunner's lesions on cystoscopy (p < 0.0001), and had significantly higher scores, i.e., more bother symptoms, on two IC/BPS questionnaires (ICPI, p = 0.0154; ICSI, p = 0.0005).
CONCLUSIONS: IC/BPS patients with low anesthetic bladder capacity have histological evidence of significantly more acute and chronic inflammation compared with patients with a non-low bladder capacity. These data provide additional evidence to support low bladder capacity as a marker of a distinct bladder-centric IC/BPS phenotype.

Entities:  

Keywords:  Bladder capacity; Bladder pain syndrome; Histology; Interstitial cystitis; Subtype

Mesh:

Substances:

Year:  2019        PMID: 31254048     DOI: 10.1007/s00192-019-04038-0

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  27 in total

Review 1.  The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis.

Authors:  Grannum R Sant; Duraisamy Kempuraj; James E Marchand; Theoharis C Theoharides
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

Review 2.  Management of interstitial cystitis/bladder pain syndrome: a urology perspective.

Authors:  Renee B Quillin; Deborah R Erickson
Journal:  Urol Clin North Am       Date:  2012-07-03       Impact factor: 2.241

3.  The interstitial cystitis symptom index and problem index.

Authors:  M P O'Leary; G R Sant; F J Fowler; K E Whitmore; J Spolarich-Kroll
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

4.  Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome.

Authors:  Marc Colaco; David S Koslov; Tristan Keys; Robert J Evans; Gopal H Badlani; Karl-Erik Andersson; Stephen J Walker
Journal:  J Urol       Date:  2014-05-17       Impact factor: 7.450

5.  Digital quantitative analysis of mast cell infiltration in interstitial cystitis.

Authors:  Yoshiyuki Akiyama; Daichi Maeda; Teppei Morikawa; Aya Niimi; Akira Nomiya; Yukio Yamada; Yasuhiko Igawa; Akiteru Goto; Masashi Fukayama; Yukio Homma
Journal:  Neurourol Urodyn       Date:  2017-10-24       Impact factor: 2.696

6.  Characterization of mast cell populations using different methods for their identification.

Authors:  Dmitri Atiakshin; Vera Samoilova; Igor Buchwalow; Werner Boecker; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2017-02-27       Impact factor: 4.304

7.  Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity.

Authors:  C Lowell Parsons; Jeffrey Dell; Edward J Stanford; Michael Bullen; Bruce S Kahn; Tracy Waxell; James A Koziol
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

8.  Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome.

Authors:  Hsin-Tzu Liu; Jia-Heng Shie; Sung-Ho Chen; Yu-Syuan Wang; Hann-Chorng Kuo
Journal:  Urology       Date:  2012-04-21       Impact factor: 2.649

9.  Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis.

Authors:  Yr Logadottir; Dick Delbro; Catharina Lindholm; Magnus Fall; Ralph Peeker
Journal:  Int J Urol       Date:  2014-04       Impact factor: 3.369

10.  Diagnosis of interstitial cystitis.

Authors:  P Hanno; R M Levin; F C Monson; C Teuscher; Z Z Zhou; M Ruggieri; K Whitmore; A J Wein
Journal:  J Urol       Date:  1990-02       Impact factor: 7.450

View more
  10 in total

1.  Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial.

Authors:  Kristina Cvach; Anna Rosamilia; Peter Dwyer; Yik Lim; Alison DeSouza; Linli Ow; Elizabeth Thomas; Christine Murray; Alison Leitch; Lore Schierlitz
Journal:  Int Urogynecol J       Date:  2021-01-16       Impact factor: 2.894

2.  Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Wan-Ru Yu; Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Biomedicines       Date:  2022-05-17

3.  Understanding bladder pain syndrome/interstitial cystitis.

Authors:  Visha Tailor; Marco Torella; Valentin Manriquez; Giuseppe Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2020-08       Impact factor: 2.894

4.  Virtual measurements of paracellular permeability and chronic inflammation via color coded pixel-wise T1 mapping.

Authors:  Nishant Singh; Irina Zabbarova; Youko Ikeda; Jodi Maranchie; Christopher Chermansky; Lesley Foley; T Kevin Hitchens; Naoki Yoshimura; Anthony Kanai; Jonathan Kaufman; Pradeep Tyagi
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

Review 5.  The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?

Authors:  Giuseppe Alessandro Digesu; Visha Tailor; Alka A Bhide; Vik Khullar
Journal:  Int Urogynecol J       Date:  2020-05-01       Impact factor: 2.894

6.  Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment.

Authors:  Wan-Ru Yu; Jia-Fong Jhang; Han-Chen Ho; Yuan-Hong Jiang; Cheng-Ling Lee; Yung-Hsiang Hsu; Hann-Chorng Kuo
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

7.  Functional and histologic imaging of urinary bladder wall after exposure to psychological stress and protamine sulfate.

Authors:  Tetsuichi Saito; Nishant Singh; T Kevin Hitchens; Lesley M Foley; Shinsuke Mizoguchi; Masahiro Kurobe; Daisuke Gotoh; Teruyuki Ogawa; Tomonori Minagawa; Osamu Ishizuka; Christopher Chermansky; Jonathan Kaufman; Naoki Yoshimura; Pradeep Tyagi
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.996

8.  Reduction of Bladder Capacity Under Anesthesia Following Multiple Recurrences and Repeated Surgeries of Hunner Lesions in Patients With Interstitial Cystitis.

Authors:  Akira Furuta; Yasuyuki Suzuki; Taro Igarashi; Takahiro Kimura; Shin Egawa; Naoki Yoshimura
Journal:  Int Neurourol J       Date:  2022-03-31       Impact factor: 2.835

9.  Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Hsiu-Jen Wang; Wan-Ru Yu; Hueih-Ling Ong; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2019-11-19       Impact factor: 4.546

Review 10.  Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.

Authors:  Hung-Yu Lin; Jian-He Lu; Shu-Mien Chuang; Kuang-Shun Chueh; Tai-Jui Juan; Yi-Chang Liu; Yung-Shun Juan
Journal:  Diagnostics (Basel)       Date:  2021-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.